Kodiak Sciences (KOD) Cash from Financing Activities (2017 - 2026)
Kodiak Sciences' (KOD) quarterly Cash from Financing Activities came in at $619000.0 in Q1 2026, up 399.19% YoY from $124000.0 in Q1 2025, and down 99.65% on a QoQ basis from $177.2 million in Q4 2025.
Powered by 
Analysis
Kodiak Sciences (KOD) Cash from Financing Activities (2017 - 2026) Analysis & Trends
Kodiak Sciences (KOD) has 10 years of Cash from Financing Activities data on file, last reported at $619000.0 in Q1 2026.
- Quarterly Cash from Financing Activities rose 399.19% year-over-year to $619000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $178.8 million (up 30359.45% YoY) and the FY2025 annual result came in at $178.3 million, up 35489.22% from the prior year.
- Cash from Financing Activities fell to $619000.0 in Q1 2026, from $177.2 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $177.2 million in Q4 2025 to a low of -$124000.0 in Q4 2023.
- A 5-year average of $11.3 million and a median of $108500.0 in 2022 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2023 — Cash from Financing Activities sank 227.84% — and 2025, when it soared 43772.52%.
- Tracing KOD's Cash from Financing Activities over 5 years: stood at $97000.0 in 2022, then slumped by 227.84% to -$124000.0 in 2023, then surged by 425.81% to $404000.0 in 2024, then soared by 43772.52% to $177.2 million in 2025, then slumped by 99.65% to $619000.0 in 2026.
- The last three Cash from Financing Activities figures came in at $619000.0 (Q1 2026), $177.2 million (Q4 2025), and $813000.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 14.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.42 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -6.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 36.24 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -273.15 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Kodiak Sciences | 2.21 Bn | 2.21 Bn | - | 2.96 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.96 Mn |
| Mar 31, 2026 | 619,000.00 |
| Dec 31, 2025 | 177.25 Mn |
| Sep 30, 2025 | 813,000.00 |
| Jun 30, 2025 | 120,000.00 |
| Mar 31, 2025 | 124,000.00 |
| Dec 31, 2024 | 404,000.00 |
| Jun 30, 2024 | 59,000.00 |
| Mar 31, 2024 | 38,000.00 |
| Dec 31, 2023 | -124,000.00 |
| Sep 30, 2023 | -12,000.00 |
| Jun 30, 2023 | 170,000.00 |
| Mar 31, 2023 | -3,000.00 |
| Dec 31, 2022 | 97,000.00 |
| Sep 30, 2022 | 78,000.00 |
| Jun 30, 2022 | 54,000.00 |
| Mar 31, 2022 | 1.67 Mn |
| Dec 31, 2021 | 2.16 Mn |
| Sep 30, 2021 | 2.03 Mn |
| Jun 30, 2021 | 2.52 Mn |